Semaglutide Off-Patent: Implications for Obesity and Metabolic Disease Treatment in India
India faces a growing epidemic of obesity and metabolic disease, exacerbated by changing food habits and sedentary lifestyles. The article discusses the impact of Semaglutide, a GLP1 therapy drug, now being off-patent in India. This development has significantly reduced its cost, making it more accessible from ₹11,000-₹18,000 per month to around ₹5,000 per month. Semaglutide, primarily an antidiabetic agent, has gained popularity as an anti-obesity/weight management drug, effective for individuals with BMI over 27 (with complications) or over 30 (without diabetes). While it offers significant weight loss and metabolic health improvements, it is crucial to remember that it's an add-on to lifestyle modifications and exercise, not a shortcut. The article emphasizes the need for broader policy changes in food and urban planning to combat the obesity crisis.
Key Points
- Semaglutide, a GLP1 therapy drug, is now off-patent in India, leading to a significant reduction in its cost and increased accessibility.
- India faces a growing epidemic of obesity and metabolic disease, linked to lifestyle changes and the 'thin-fat' phenotype.
- GLP1 therapy, like Semaglutide, is effective for weight reduction and improving metabolic health in specific patient groups.
- It is crucial to understand that Semaglutide is an adjunct to lifestyle modifications (diet and exercise), not a standalone solution or quick fix.
- Beyond drug access, broader public health interventions, including food policy changes and urban planning for physical activity, are necessary to address the obesity crisis.
Exam Facts
- Semaglutide is a GLP1 therapy drug.
- Novo Nordisk's patent for semaglutide expired on March 22.
- The cost of a Semaglutide pen has dropped from ₹11,000-₹18,000 to around ₹5,000 per month.
- GLP1 therapy is approved for weight reduction in individuals with BMI over 27 (with complications) or over 30 (without diabetes).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.